Release date: 19 November 2021
Promoter – Financial Intermediary
POCARED DIAGNOSTICS LTD
Developing a real-time, high-volume, reagent-free in vitro diagnostics system for infectious diseases, with a focus on Antimicrobial Susceptibility Testing ("AST") and Antimicrobial Resistance ("AMR").
The proposed transaction will support research and development (R&D) investments required to bring products to the market addressing high unmet medical needs, in a growing patient population, preserving and cultivating highly skilled employment opportunities.
- Services - Professional, scientific and technical activities
Proposed EIB finance (Approximate amount)
EUR 22 million
Total cost (Approximate amount)
EUR 46 million
The project mainly concerns investments in research and development (R&D) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2014/52/EU amending the Directive 2011/92/EC.
The Promoter is a private company, not operating in the utilities sector and does not have the status of a contracting authority; thus the project is not covered by the EU directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects.
Under appraisal - 19/11/2021
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).